Business Description
NovoCure Ltd
NAICS : 339112
SIC : 5047
ISIN : BRN2VCBDR008
Share Class Description:
BSP:N2VC34: BRDRTotal Employee Number:
1,605Description
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.84 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.71 | |||||
Debt-to-EBITDA | -1.76 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.49 | |||||
Beneish M-Score | -3 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.6 | |||||
3-Year EBITDA Growth Rate | -13.1 | |||||
3-Year EPS without NRI Growth Rate | -11.5 | |||||
3-Year Book Growth Rate | -10.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.46 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 2.38 | |||||
9-Day RSI | 10.61 | |||||
14-Day RSI | 23.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.9 | |||||
Quick Ratio | 2.7 | |||||
Cash Ratio | 1.99 | |||||
Days Inventory | 88.74 | |||||
Days Sales Outstanding | 47.88 | |||||
Days Payable | 247.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | 11.32 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.2 | |||||
Operating Margin % | -27.19 | |||||
Net Margin % | -25.66 | |||||
EBITDA Margin % | -19.77 | |||||
FCF Margin % | -7.18 | |||||
OCF Margin % | -4.04 | |||||
ROE % | -50.19 | |||||
ROA % | -15.88 | |||||
ROIC % | -36.16 | |||||
3-Year ROIIC % | -73.8 | |||||
ROC (Joel Greenblatt) % | -101.48 | |||||
ROCE % | -27.16 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.36 | |||||
PB Ratio | 4.95 | |||||
Price-to-Tangible-Book | 4.95 | |||||
EV-to-EBIT | -9.68 | |||||
EV-to-Forward-EBIT | -18.22 | |||||
EV-to-EBITDA | -10.8 | |||||
EV-to-Revenue | 2.13 | |||||
EV-to-Forward-Revenue | 2.03 | |||||
EV-to-FCF | -29.94 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Projected-FCF | 16.86 | |||||
Price-to-Median-PS-Value | 0.17 | |||||
| Price-to-Net-Current-Asset-Value | 9.32 | |||||
Earnings Yield (Greenblatt) % | -10.34 | |||||
FCF Yield % | -2.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NovoCure Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 3,638.855 | ||
| EPS (TTM) (R$) | -8.208 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 23.28 | ||
| 14-Day ATR (R$) | 0.164434 | ||
| 20-Day SMA (R$) | 8.396 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (R$) | 5.29 - 9.29 | ||
| Shares Outstanding (Mil) | 115.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NovoCure Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NovoCure Ltd Stock Events
| Event | Date | Price (R$) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 08:00 | In 128 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 127 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-24 08:00 | In 30 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | In 29 days | ||
| General meeting for 2026 | 2026-06-03 09:00 | 8.70 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 08:00 | 6.46 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 6.46 (+0.00%) | ||
| Guidance call for 2026 | 2026-03-10 11:20 | -- | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 08:00 | -- | ||
| Annual report for 2025 | 2026-02-26 | -- |
Show
Entries
NovoCure Ltd Frequently Asked Questions
What is NovoCure Ltd(BSP:N2VC34)'s stock price today?
The current price of BSP:N2VC34 is R$7.08. The 52 week high of BSP:N2VC34 is R$9.29 and 52 week low is R$5.29.
When is next earnings date of NovoCure Ltd(BSP:N2VC34)?
The next earnings date of NovoCure Ltd(BSP:N2VC34) is 2026-07-24 Est..
Does NovoCure Ltd(BSP:N2VC34) pay dividends? If so, how much?
NovoCure Ltd(BSP:N2VC34) does not pay dividend.
Press Release
Articles on NovoCure Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers